Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth Recovers
I'm LongbridgeAI, I can summarize articles.Bloom Burton analyst David Martin maintained a Buy rating on Microbix Biosystems with a C$0.40 price target on August 14. Despite quarterly results missing forecasts and a dip in antigen revenue, Martin cites solid year-over-year growth driven by the normalization of China-related sales. He anticipates stabilizing Chinese demand at a sustainable rate, supporting future revenue and justifying the positive outlook.
Bloom Burton analyst David Martin PhD maintained a Buy rating on Microbix Biosystms on August 14 and set a price target of C$0.40.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
David Martin PhD has given his Buy rating due to a combination of factors that point to a recovery and normalization in Microbix’s core operations. While the latest quarterly results fell short of his forecasts and antigen revenue declined versus the prior quarter, he notes that year‑over‑year growth is solid and reflects the return of China‑related antigen sales that were absent last year.
He also highlights that Chinese demand, though unlikely to reach the exceptional levels seen during the pneumonia surge in FY2024, is stabilizing at a more sustainable run‑rate that should underpin future revenue. In his view, this transition back to normalized volumes, together with the company’s broader antigen franchise and operational resilience, supports a favorable risk‑reward profile and justifies maintaining a Buy recommendation on MBX.